Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

ABSTRACT:

Background

Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial.

Methods

This is a retrospective review from April 2015 to May 2016 at a single academic institution where 16 ATC patients receiving targeted therapy outside of a clinical trial were studied. Ten patients (eight BRAF wild type and two BRAF^V600E mutant tumors) were started on lenvatinib, and six with BRAF^V600E-mutated tumors received a combination of dabrafenib plus trametinib. Best response evaluated by RECIST v1.1, progression-free survival, and overall survival were determined. Adverse ev

SUBMITTER: Iyer PC 

PROVIDER: S-EPMC6425981 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature